cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Macrogenics Inc
8 own
15 watching
Current Price
$17.93
$0.74
(4.3%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
396.5M
52-Week High
52-Week High
18.85000
52-Week Low
52-Week Low
4.29000
Average Volume
Average Volume
1.73M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization396.5M
icon52-Week High18.85000
icon52-Week Low4.29000
iconAverage Volume1.73M
iconDividend Yield--
iconP/E Ratio--
What does the Macrogenics Inc do?
MacroGenics, Inc., a biopharmaceutical company, focuses on the discovery and development of antibody-based therapeutics for the treatment of cancer primarily by modulating the human immune system, as well as various autoimmune disorders and infectious diseases in the United States. The company's advanced clinical product candidate is Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets human epidermal growth factor receptor 2-expressing tumors, such as various breast and gastroesophageal cancers. It also develops Enoblituzumab, a monoclonal antibody, which is in Phase 1 clinical trial as monotherapy in multiple solid tumor types, as well as in combination therapy with either an anti-PD-1 antibody or an anti-CTLA-4 antibody; Flotetuzumab, a DART molecule that targets CD123 and CD3; MGD007, a DART molecule, which targets glycoprotein A33 and CD3; Duvortuxizumab, a DART molecule that targets both CD19 and CD3; MGD009, a molecule in its B7-H3 franchise; MGA012, a monoclonal antibody, which targets PD-1; MGD013, a DART molecule that enables the co-blockade with a single recombinant agent of two immune checkpoint molecules; and MGC018, a B7-H3 antibody-drug conjugate. In addition, the company's products include MGD010, a DART molecule designed to address limitations of existing B cell-targeted therapies by binding to the CD32B and CD79B proteins found on human B cells; Teplizumab, an anti-CD3 monoclonal antibody to treat type 1 diabetes; and MGD014, a DART molecule that targets human immunodeficiency virus, or HIV-infected cells, and CD3-expressing T cells. It has collaboration and license agreements with Janssen Biotech, Inc.; Les Laboratoires Servier and Institut de Recherches Servier; Boehringer Ingelheim GmbH; Pfizer, Inc.; and Green Cross Corp. MacroGenics, Inc. was founded in 2000 and is headquartered in Rockville, Maryland.
Read More
How much money does Macrogenics Inc make?
News & Events about Macrogenics Inc.
Zolmax
10 months ago
MacroGenics, Inc. (NASDAQ:MGNX Get Rating) has been assigned a consensus rating of Moderate Buy from the thirteen analysts that are currently covering the stock, Marketbeat.com reports. Five equities research analysts have rated the stock with a hold recommendation and five have assigned a buy ...
Globe Newswire
11 months ago
ROCKVILLE, MD, March 22, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today reported that following the U.S. Food and Drug Administrations (FDA) ...
Zolmax
1 year ago
MacroGenics, Inc. (NASDAQ:MGNX Get Rating) major shareholder Target N. V. Biotech acquired 500,000 shares of the businesss stock in a transaction dated Tuesday, February 14th. The stock was acquired at an average price of $5.07 per share, for a total transaction of $2,535,000.00. Following the ...
Zolmax
1 year ago
MacroGenics, Inc. (NASDAQ:MGNX Get Rating) major shareholder Target N. V. Biotech acquired 500,000 shares of the businesss stock in a transaction dated Tuesday, February 14th. The stock was acquired at an average price of $5.07 per share, for a total transaction of $2,535,000.00. Following the ...
Ticker Report
1 year ago
MacroGenics, Inc. (NASDAQ:MGNX Get Rating) major shareholder Target N. V. Biotech acquired 500,000 shares of the businesss stock in a transaction dated Tuesday, February 14th. The stock was acquired at an average price of $5.07 per share, for a total transaction of $2,535,000.00. ...
Frequently Asked Questions
Frequently Asked Questions
What is Macrogenics Inc share price today?
plus_minus_icon
Can Indians buy Macrogenics Inc shares?
plus_minus_icon
How can I buy Macrogenics Inc shares from India?
plus_minus_icon
Can Fractional shares of Macrogenics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Macrogenics Inc stocks?
plus_minus_icon
What is today’s traded volume of Macrogenics Inc?
plus_minus_icon
What is today’s market capitalisation of Macrogenics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Macrogenics Inc?
plus_minus_icon
What percentage is Macrogenics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Macrogenics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$17.93
$0.74
(4.3%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00